Inventor
CHARISSE KLAUS
US43 patents
⚠️ This page may combine multiple inventors who share the name “CHARISSE KLAUS”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ALNYLAM PHARMACEUTICALS INC
38 patentsUS9796974B2Oct 24, 2017
Modified RNAi agents
ALNYLAM PHARMACEUTICALS INC119 citations99
US9399775B2Jul 26, 2016
RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
ALNYLAM PHARMACEUTICALS INC51 citations98
US10668170B2Jun 2, 2020
Modified RNAi agents
ALNYLAM PHARMACEUTICALS INC22 citations94
US9249415B2Feb 2, 2016
Complement component C5 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC24 citations94
US9783806B2Oct 10, 2017
TMPRSS6 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC16 citations93
US9850488B2Dec 26, 2017
Complement component C5 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC11 citations92
US9574192B2Feb 21, 2017
Serapina1 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC14 citations92
US11406716B2Aug 9, 2022
Modified RNAi agents
ALNYLAM PHARMACEUTICALS INC8 citations86
US10570391B2Feb 25, 2020
RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
ALNYLAM PHARMACEUTICALS INC12 citations86
US11504391B1Nov 22, 2022
Modified RNA agents with reduced off-target effect
ALNYLAM PHARMACEUTICALS INC18 citations84
US10913950B2Feb 9, 2021
TMPRSS6 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC5 citations84
US10238749B2Mar 26, 2019
Angiotensinogen (AGT) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC12 citations84
US10125369B2Nov 13, 2018
PCSK9 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC9 citations84
US10030244B2Jul 24, 2018
Serpina1 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC6 citations84
US9701963B2Jul 11, 2017
Complement component C5 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC9 citations84
US9376680B2Jun 28, 2016
Serpinc1 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC7 citations84
US10995336B2May 4, 2021
Serpina1 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC8 citations83
US11873491B2Jan 16, 2024
Complement component C5 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC2 citations73
US11419942B2Aug 23, 2022
Angiotensinogen (AGT) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC2 citations73
US11162098B2Nov 2, 2021
Complement component C5 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC2 citations73
US10988768B2Apr 27, 2021
TMPRSS6 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC3 citations73
US10920223B2Feb 16, 2021
Serpina1 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC2 citations73
US10814007B2Oct 27, 2020
Angiotensinogen (AGT) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC3 citations73
US10683504B2Jun 16, 2020
Serpina1 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC2 citations73
US9970006B2May 15, 2018
Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) genes
ALNYLAM PHARMACEUTICALS INC4 citations73
US9725718B2Aug 8, 2017
Compositions and methods for inhibition of expression of protein C (PROC) genes
ALNYLAM PHARMACEUTICALS INC3 citations73
US11597932B2Mar 7, 2023
Chirally-enriched double-stranded RNA agents
ALNYLAM PHARMACEUTICALS INC3 citations70
US12590305B2Mar 31, 2026
Complement component C5 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations62
US12460206B2Nov 4, 2025
PCSK9 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations62
US12290573B2May 6, 2025
Modified RNAi agents
ALNYLAM PHARMACEUTICALS INC0 citations62
US12275938B2Apr 15, 2025
Modified RNA agents with reduced off-target effect
ALNYLAM PHARMACEUTICALS INC0 citations62
US12247203B2Mar 11, 2025
Modified RNA agents with reduced off-target effect
ALNYLAM PHARMACEUTICALS INC0 citations62
US12071619B2Aug 27, 2024
SERPINA1 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations62
US11725207B2Aug 15, 2023
Serpina1 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC1 citations62
US11118181B2Sep 14, 2021
Compositions and methods for inhibition of expression of protein C (PROC) genes
ALNYLAM PHARMACEUTICALS INC0 citations62
US12397013B2Aug 26, 2025
Extrahepatic delivery
ALNYLAM PHARMACEUTICALS INC0 citations61
US12005074B2Jun 11, 2024
Extrahepatic delivery
ALNYLAM PHARMACEUTICALS INC0 citations61
US10273478B2Apr 30, 2019
Compositions and methods for inhibition of expression of protein C (PROC) genes
ALNYLAM PHARMACEUTICALS INC0 citations52
BETTENCOURT BRIAN
2 patentsUS9228188B2Jan 5, 2016
Compositions and method for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-related gene expression
BETTENCOURT BRIAN8 citations82
US9315813B2Apr 19, 2016
Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) genes
BETTENCOURT BRIAN3 citations71